B3GAT2

Summary

B3GAT2 (beta-1,3-glucuronyltransferase 2, HGNC:922) is a protein-coding gene on chromosome 6q13, encoding Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 2 (Q9NPZ5). Involved in the biosynthesis of L2/HNK-1 carbohydrate epitope on both glycolipids and glycoproteins.

The product of this gene is a transmembrane protein belonging to the glucuronyltransferase family, and catalyzes the transfer of a beta-1,3 linked glucuronic acid to a terminal galactose in different glycoproteins or glycolipids containing a Gal-beta-1-4GlcNAc or Gal-beta-1-3GlcNAc residue. The encoded protein is involved in the synthesis of the human natural killer-1 (HNK-1) carbohydrate epitope, a sulfated trisaccharide implicated in cellular migration and adhesion in the nervous system.

Source: NCBI Gene 135152 — RefSeq curated summary.

At a glance

• GWAS associations: 6
• Clinical variants (ClinVar): 102 total — 1 pathogenic, 1 likely-pathogenic
• Phenotypes (HPO): 1
• MANE Select transcript: NM_080742

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:922
Approved symbol	B3GAT2
Name	beta-1,3-glucuronyltransferase 2
Location	6q13
Locus type	gene with protein product
Status	Approved
Aliases	GlcAT-S
Ensembl gene	ENSG00000112309
Ensembl biotype	protein_coding
OMIM	607497
Entrez	135152

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 2 protein_coding

ENST00000230053, ENST00000615536

RefSeq mRNA: 1 — MANE Select: NM_080742 NM_080742

CCDS: CCDS4974

Canonical transcript exons

ENST00000230053 — 4 exons

Exon	Start	End
ENSE00000758544	70861830	70861978
ENSE00003992269	70856679	70861749
ENSE00003992279	70955839	70957060
ENSE00003992289	70894128	70894272

Expression profiles

Bgee: expression breadth ubiquitous, 207 present calls, max score 96.01.

FANTOM5 (CAGE): breadth broad, TPM avg 1.4700 / max 95.4153, expressed in 196 samples.

FANTOM5 promoters (10 alternative TSS)

Promoter ID	TPM avg	Samples expressed
74322	0.5765	95
74323	0.1852	80
74319	0.1842	96
74317	0.1536	78
74318	0.1282	74
74316	0.0824	50
74321	0.0744	53
74324	0.0463	31
74320	0.0240	12
74315	0.0152	5

Top tissues by expression

263 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ventricular zone	UBERON:0003053	96.01	gold quality
entorhinal cortex	UBERON:0002728	92.65	gold quality
embryo	UBERON:0000922	92.48	gold quality
ganglionic eminence	UBERON:0004023	92.48	gold quality
buccal mucosa cell	CL:0002336	91.63	gold quality
pons	UBERON:0000988	91.52	gold quality
Brodmann (1909) area 46	UBERON:0006483	89.56	gold quality
postcentral gyrus	UBERON:0002581	88.64	gold quality
Ammon’s horn	UBERON:0001954	88.20	gold quality
endothelial cell	CL:0000115	87.07	gold quality
corpus callosum	UBERON:0002336	86.74	gold quality
parietal lobe	UBERON:0001872	86.43	gold quality
secondary oocyte	CL:0000655	86.41	gold quality
superior frontal gyrus	UBERON:0002661	85.81	gold quality
oocyte	CL:0000023	85.55	gold quality
medulla oblongata	UBERON:0001896	85.46	gold quality
temporal lobe	UBERON:0001871	85.32	gold quality
hypothalamus	UBERON:0001898	85.20	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	84.36	gold quality
superior vestibular nucleus	UBERON:0007227	84.34	gold quality
spinal cord	UBERON:0002240	83.32	gold quality
Brodmann (1909) area 23	UBERON:0013554	82.96	gold quality
midbrain	UBERON:0001891	82.62	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	82.52	gold quality
substantia nigra	UBERON:0002038	82.49	gold quality
amygdala	UBERON:0001876	82.21	gold quality
ventral tegmental area	UBERON:0002691	81.97	gold quality
cerebral cortex	UBERON:0000956	81.63	gold quality
medial globus pallidus	UBERON:0002477	81.45	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	81.19	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-GEOD-137537	yes	5.84
E-MTAB-6386	no	29.78
E-ANND-3	no	3.83

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

22 targeting B3GAT2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3912-5P	99.95	66.11	925
HSA-MIR-589-3P	99.91	69.62	2088
HSA-MIR-6762-3P	99.66	66.94	1188
HSA-MIR-298	99.63	67.56	1916
HSA-MIR-6832-5P	99.58	64.82	1132
HSA-MIR-141-5P	99.57	67.86	897
HSA-MIR-136-5P	99.50	67.26	1153
HSA-MIR-3123	99.47	67.15	2693
HSA-MIR-21-5P	99.46	70.54	1035
HSA-MIR-3140-5P	99.39	69.04	1136
HSA-MIR-5683	99.36	68.59	2083
HSA-MIR-888-5P	99.30	70.15	1855
HSA-MIR-590-5P	99.25	70.76	930
HSA-MIR-877-3P	99.09	68.10	1637
HSA-MIR-4718	98.55	68.61	814
HSA-MIR-548AO-5P	98.55	69.57	1362
HSA-MIR-548AX	98.55	69.58	1362
HSA-MIR-1245B-3P	98.01	68.91	1387
HSA-MIR-219B-5P	97.91	65.80	531
HSA-MIR-5196-3P	97.57	65.98	979
HSA-MIR-5579-3P	97.00	68.81	1111
HSA-MIR-4732-5P	90.07	64.77	412

Literature-anchored findings (GeneRIF, showing 5)

• human GlcAT-S gene-located on human chromosome 6 encodes a protein involved in biosynthesis of HNK-1 carbohydrate epitope on glycoproteins. (PMID:12522689)
• Residues interacting with UDP molecule, which is a part of the donor substrate, are highly conserved between GlcAT-P and GlcAT-S (PMID:16897771)
• results suggest that effects on biosynthesis of the neuronal epitope HNK-1, through common B3GAT2 variation, could increase the risk of SCZ, possibly by decreasing cortical area. (PMID:20950796)
• B3GAT2 and ZNF793 are hypermethylated in BE, and the methylation status of these genes can be used to detect BE in tissue samples. (PMID:26545406)
• The study identified a region on chromosome 6 comprising the genes SMAP1, B3GAT2, and RIMS1 as novel susceptibility locus for pediatric venous thromboembolism. (PMID:28011674)

Cross-species orthologs

9 orthologs

Organism	Symbol	Gene ID
danio_rerio	b3gat2	ENSDARG00000030733
mus_musculus	B3gat2	ENSMUSG00000026156
rattus_norvegicus	B3gat2	ENSRNOG00000046852
caenorhabditis_elegans	glct-4	WBGENE00008160
caenorhabditis_elegans	glct-5	WBGENE00008293
caenorhabditis_elegans	glct-2	WBGENE00008479
caenorhabditis_elegans	glct-1	WBGENE00011650
caenorhabditis_elegans	glct-3	WBGENE00011781
caenorhabditis_elegans		WBGENE00019546

Paralogs (2): B3GAT1 (ENSG00000109956), B3GAT3 (ENSG00000149541)

Protein

Protein identifiers

Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 2 — Q9NPZ5 (reviewed: Q9NPZ5)

Alternative names: Beta-1,3-glucuronyltransferase 2, GlcAT-D, UDP-glucuronosyltransferase S

All UniProt accessions (2): Q9NPZ5, A0A087WXU9

UniProt curated annotations — full annotation on UniProt →

Function. Involved in the biosynthesis of L2/HNK-1 carbohydrate epitope on both glycolipids and glycoproteins.

Subunit / interactions. Homodimer.

Subcellular location. Golgi apparatus membrane.

Tissue specificity. Expressed in the trachea, retina, spinal cord, hippocampus and other brain regions, and, at lower levels, in testis and ovary.

Pathway. Protein modification; protein glycosylation.

Similarity. Belongs to the glycosyltransferase 43 family.

RefSeq proteins (1): NP_542780* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR005027	Glyco_trans_43	Family
IPR029044	Nucleotide-diphossugar_trans	Homologous_superfamily

Pfam: PF03360

Catalyzed reactions (Rhea), 1 shown:

• 3-O-(beta-D-galactosyl-(1->3)-beta-D-galactosyl-(1->4)-beta-D-xylosyl)-L-seryl-[protein] + UDP-alpha-D-glucuronate = 3-O-(beta-D-GlcA-(1->3)-beta-D-Gal-(1->3)-beta-D-Gal-(1->4)-beta-D-Xyl)-L-seryl-[protein] + UDP + H(+) (RHEA:24168)

UniProt features (40 total): strand 12, helix 10, binding site 7, topological domain 2, site 2, glycosylation site 2, region of interest 2, chain 1, transmembrane region 1, active site 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
2D0J	X-RAY DIFFRACTION	2

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NPZ5-F1	85.88	0.68

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (3): 218 (interaction with galactose moiety of substrate glycoprotein); 310 (interaction with galactose moiety of substrate glycoprotein); 273 (proton donor/acceptor)

Ligand- & substrate-binding residues (7): 160; 185–187; 187; 300–302; 87–89; 118; 155

Glycosylation sites (2): 67, 292

Function

Pathways and Gene Ontology

Reactome pathways

6 pathways

ID	Pathway
R-HSA-1971475	Glycosaminoglycan-protein linkage region biosynthesis
R-HSA-1430728	Metabolism
R-HSA-1630316	Glycosaminoglycan metabolism
R-HSA-1638091	Heparan sulfate/heparin (HS-GAG) metabolism
R-HSA-1793185	Chondroitin sulfate/dermatan sulfate metabolism
R-HSA-71387	Metabolism of carbohydrates and carbohydrate derivatives

MSigDB gene sets: 57 (showing top): GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS, GOBP_CHONDROITIN_SULFATE_PROTEOGLYCAN_BIOSYNTHETIC_PROCESS, GOBP_CARBOHYDRATE_DERIVATIVE_BIOSYNTHETIC_PROCESS, GOBP_CARBOHYDRATE_METABOLIC_PROCESS, GOBP_CHONDROITIN_SULFATE_PROTEOGLYCAN_METABOLIC_PROCESS, GOBP_PROTEIN_O_LINKED_GLYCOSYLATION, GOBP_GLYCOPROTEIN_METABOLIC_PROCESS, REACTOME_METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES, GOMF_HEXOSYLTRANSFERASE_ACTIVITY, GOMF_GLYCOSYLTRANSFERASE_ACTIVITY, GOMF_GLUCURONOSYLTRANSFERASE_ACTIVITY, GOMF_UDP_GLYCOSYLTRANSFERASE_ACTIVITY, KEGG_GLYCOSAMINOGLYCAN_BIOSYNTHESIS_CHONDROITIN_SULFATE, MEISSNER_BRAIN_HCP_WITH_H3K4ME3_AND_H3K27ME3, GOBP_GLYCOPROTEIN_BIOSYNTHETIC_PROCESS

GO Biological Process (4): carbohydrate metabolic process (GO:0005975), carbohydrate biosynthetic process (GO:0016051), chondroitin sulfate proteoglycan biosynthetic process (GO:0050650), obsolete protein glycosylation (GO:0006486)

GO Molecular Function (3): galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase activity (GO:0015018), metal ion binding (GO:0046872), transferase activity (GO:0016740)

GO Cellular Component (3): Golgi membrane (GO:0000139), Golgi apparatus (GO:0005794), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Glycosaminoglycan metabolism	3
Metabolism of carbohydrates and carbohydrate derivatives	1
Metabolism	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
primary metabolic process	1
carbohydrate metabolic process	1
biosynthetic process	1
proteoglycan biosynthetic process	1
chondroitin sulfate proteoglycan metabolic process	1
protein O-linked glycosylation via xylose	1
glucuronosyltransferase activity	1
cation binding	1
catalytic activity	1
Golgi apparatus	1
bounding membrane of organelle	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

960 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
B3GAT2	UGT2B7	P16662	914
B3GAT2	CYP1A2	P05177	886
B3GAT2	CYP2E1	P05181	886
B3GAT2	SLC35A2	P78381	886
B3GAT2	UGT1A6	P19224	880
B3GAT2	UGT2B15	P23765	877
B3GAT2	UGT1A4	P22310	876
B3GAT2	UGT1A10	Q9HAW8	852
B3GAT2	CYP3A4	P05184	834
B3GAT2	CYP2C19	P33259	833
B3GAT2	UGT1A8	Q9HAW9	833
B3GAT2	UGT1A7	Q9HAW7	830
B3GAT2	UGT2B17	O75795	827
B3GAT2	UGT1A1	P22309	819
B3GAT2	UGT2B28	Q9BY64	815

IntAct

5 interactions, top by confidence:

A	B	Type	Score
B3GAT2	SEPTIN9	psi-mi:“MI:0915”(physical association)	0.400
B3GAT2	FAM20B	psi-mi:“MI:0914”(association)	0.350
B3GAT2	HSPA5	psi-mi:“MI:0914”(association)	0.350

BioGRID (18): SEPT9 (Proximity Label-MS), FHL2 (Affinity Capture-MS), HSPA5 (Affinity Capture-MS), RMND1 (Affinity Capture-MS), SEPN1 (Affinity Capture-MS), CACNA2D2 (Affinity Capture-MS), ITGA7 (Affinity Capture-MS), FAM20B (Affinity Capture-MS), FRAS1 (Affinity Capture-MS), CLSTN3 (Affinity Capture-MS), DNAJC11 (Affinity Capture-MS), TMEM59 (Affinity Capture-MS), ABHD12 (Affinity Capture-MS), ASIC1 (Affinity Capture-MS), LRP6 (Affinity Capture-MS)

ESM2 similar proteins: A0A0P0WL81, A2X933, A2XFT5, A2XFT6, A2ZAX5, A2ZF66, A2ZHL0, A2ZI32, B8AIZ4, B9FCV3, B9FKP6, C7J0P3, O35789, P45895, P59270, Q0D3C8, Q0E1Z0, Q10MK2, Q10MX2, Q10N05, Q2QXP0, Q2QYF3, Q2R2W8, Q2RB59, Q53JI9, Q5CAZ6, Q5CB03, Q5CB04, Q5D0W8, Q5QM25, Q5Z980, Q653F4, Q67V61, Q69XK5, Q6AT32, Q6Z3Y6, Q6Z5M3, Q75HA6, Q7XTB2, Q8GZ81

Diamond homologs: O35789, O94766, O97422, P58158, P59270, Q09363, Q10N05, Q5CAZ6, Q5CB03, Q5CB04, Q5QM25, Q5ZCC5, Q653F4, Q6AT32, Q7XTB2, Q8L707, Q8S626, Q9CW73, Q9NPZ5, Q9P2W7, Q9SXC4, Q9VLA1, Q9VTG7, Q9WU47, Q9Z137, Q9FH90, Q6Z3Y6, Q75L84, Q9ZQC6, B9FCV3

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

102 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	1
Uncertain significance	86
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
1710926	GRCh37/hg19 6q13(chr6:71105038-75200617)x1	Pathogenic
3391830	GRCh37/hg19 6q13(chr6:71236776-73908689)x1	Likely pathogenic

SpliceAI

1333 predictions. Top by Δscore:

Variant	Effect	Δscore
6:70856854:CTCAG:C	acceptor_loss	1.0000
6:70856856:CAG:C	acceptor_loss	1.0000
6:70856857:A:AG	acceptor_gain	1.0000
6:70856857:A:AT	acceptor_loss	1.0000
6:70856857:AG:A	acceptor_gain	1.0000
6:70856857:AGG:A	acceptor_gain	1.0000
6:70856858:G:A	acceptor_gain	1.0000
6:70856858:G:GG	acceptor_gain	1.0000
6:70856858:GGG:G	acceptor_gain	1.0000
6:70857004:G:GT	donor_gain	1.0000
6:70857026:TCCTG:T	donor_loss	1.0000
6:70857029:TGGTA:T	donor_loss	1.0000
6:70857030:GGT:G	donor_loss	1.0000
6:70857031:GTA:G	donor_loss	1.0000
6:70857032:T:G	donor_loss	1.0000
6:70861978:CCTT:C	acceptor_gain	1.0000
6:70861981:T:TC	acceptor_gain	1.0000
6:70894123:CTCA:C	donor_loss	1.0000
6:70894125:CA:C	donor_loss	1.0000
6:70894126:ACCT:A	donor_loss	1.0000
6:70894127:C:CA	donor_loss	1.0000
6:70894268:CGCAT:C	acceptor_gain	1.0000
6:70894269:GCAT:G	acceptor_gain	1.0000
6:70894270:CAT:C	acceptor_gain	1.0000
6:70894270:CATC:C	acceptor_gain	1.0000
6:70894271:AT:A	acceptor_gain	1.0000
6:70894271:ATCT:A	acceptor_loss	1.0000
6:70894272:TC:T	acceptor_loss	1.0000
6:70894273:C:CC	acceptor_gain	1.0000
6:70894273:C:CG	acceptor_loss	1.0000

AlphaMissense

2079 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:70861735:G:C	H300Q	1.000
6:70861735:G:T	H300Q	1.000
6:70861737:G:C	H300D	1.000
6:70861737:G:T	H300N	1.000
6:70861738:C:A	W299C	1.000
6:70861738:C:G	W299C	1.000
6:70861740:A:G	W299R	1.000
6:70861740:A:T	W299R	1.000
6:70861836:G:C	C293W	1.000
6:70861837:C:T	C293Y	1.000
6:70861858:A:G	L286P	1.000
6:70861885:A:G	L277P	1.000
6:70861885:A:T	L277H	1.000
6:70861888:A:G	F276S	1.000
6:70861896:T:A	E273D	1.000
6:70861896:T:G	E273D	1.000
6:70861897:T:A	E273V	1.000
6:70861899:T:A	Q272H	1.000
6:70861899:T:G	Q272H	1.000
6:70861929:A:C	F262L	1.000
6:70861929:A:T	F262L	1.000
6:70861930:A:C	F262C	1.000
6:70861930:A:G	F262S	1.000
6:70861931:A:G	F262L	1.000
6:70861972:G:T	A248D	1.000
6:70861973:C:G	A248P	1.000
6:70861974:A:C	F247L	1.000
6:70861974:A:T	F247L	1.000
6:70861975:A:G	F247S	1.000
6:70861976:A:G	F247L	1.000

dbSNP variants (sampled 300 via entrez): RS1000091197 (6:70939799 A>G,T), RS1000149473 (6:70927995 T>C), RS1000220518 (6:70889163 T>C), RS1000247176 (6:70906783 C>T), RS1000252966 (6:70945427 C>G,T), RS1000276170 (6:70907318 G>A), RS1000336470 (6:70873557 A>C), RS1000363105 (6:70947668 A>C), RS1000363823 (6:70885062 G>A,C), RS1000413071 (6:70878457 C>A,T), RS1000414171 (6:70918557 T>G), RS1000414777 (6:70919265 T>G), RS1000419985 (6:70861496 A>G), RS1000439655 (6:70938180 G>A), RS1000527443 (6:70908391 T>C)

Disease associations

OMIM: gene MIM:607497 | disease phenotypes: MIM:209850

GenCC curated gene-disease

Mondo (1): autism (MONDO:0005260)

Orphanet (0):

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0000717	Autism

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST000982_4	F-cell distribution in sickle cell anaemia	9.000000e-07
GCST001762_575	Obesity-related traits	7.000000e-06
GCST003518_15	Daytime sleep phenotypes	4.000000e-06
GCST004012_1	Venous thromboembolism	3.000000e-06
GCST004012_2	Venous thromboembolism	1.000000e-06
GCST012490_193	Femur bone mineral density x serum urate levels interaction	4.000000e-08

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0004576	fetal hemoglobin measurement
EFO:0004736	aspartate aminotransferase measurement
EFO:0007828	daytime rest measurement
EFO:0004531	urate measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D001321	Autistic Disorder	F03.625.164.113.500

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

26 total (human), top 26 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, affects cotreatment	4
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
trichostatin A	increases expression, decreases expression	1
benzo(e)pyrene	increases methylation	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression, affects cotreatment	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression, increases expression	1
dorsomorphin	increases expression, affects cotreatment, decreases expression	1
jinfukang	decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Arsenic	affects methylation	1
Benzo(a)pyrene	affects methylation, increases methylation	1
Cisplatin	decreases expression	1
Copper	decreases expression, affects cotreatment	1
Diazinon	increases methylation	1
Lipopolysaccharides	increases expression, affects response to substance, affects cotreatment	1
Methapyrilene	increases methylation	1
Methotrexate	decreases expression	1
Sodium Dodecyl Sulfate	increases expression	1
Tobacco Smoke Pollution	decreases expression	1
Tretinoin	decreases expression	1
1-Methyl-4-phenylpyridinium	decreases expression	1
Aflatoxin B1	decreases methylation	1
Okadaic Acid	increases expression	1
Acrylamide	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00211796	PHASE4	COMPLETED	Divalproex Sodium ER in Adult Autism
NCT00391261	PHASE4	COMPLETED	An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
NCT00409747	PHASE4	COMPLETED	Minocycline to Treat Childhood Regressive Autism
NCT00576732	PHASE4	COMPLETED	A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder
NCT00844753	PHASE4	COMPLETED	Atomoxetine, Placebo and Parent Management Training in Autism
NCT01028820	PHASE4	COMPLETED	FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
NCT01098383	PHASE4	UNKNOWN	Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Spectrum Disorders
NCT01333865	PHASE4	COMPLETED	A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
NCT01337700	PHASE4	COMPLETED	Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
NCT01695200	PHASE4	COMPLETED	Omega-3 Fatty Acids in Autism Spectrum Disorders
NCT02069977	PHASE4	UNKNOWN	Study to Evaluate the Efficacy and Safety of Aripiprazole
NCT02096952	PHASE4	COMPLETED	Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
NCT02199925	PHASE4	UNKNOWN	An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum
NCT02235467	PHASE4	COMPLETED	Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism
NCT02255565	PHASE4	COMPLETED	Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study
NCT02940574	PHASE4	COMPLETED	Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
NCT03333629	PHASE4	COMPLETED	Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes
NCT03337646	PHASE4	COMPLETED	Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
NCT03538431	PHASE4	COMPLETED	Improving Driving in Young People With Autism Spectrum Disorders
NCT03757585	PHASE4	COMPLETED	Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
NCT04903353	PHASE4	COMPLETED	Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
NCT05063656	PHASE4	COMPLETED	Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin
NCT05146245	PHASE4	UNKNOWN	Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT
NCT05916339	PHASE4	RECRUITING	AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05954052	PHASE4	TERMINATED	A Study of Glutathione in Children With Autism Spectrum Disorder
NCT06853665	PHASE4	RECRUITING	The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
NCT07054697	PHASE4	COMPLETED	Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder
NCT07161804	PHASE4	COMPLETED	Pilot RCT Using Homeopathic Medicines in ASD
NCT07439042	PHASE4	NOT_YET_RECRUITING	Buspirone for Anxiety in Autistic Youth
NCT00036231	PHASE3	TERMINATED	Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction
NCT00036244	PHASE3	COMPLETED	Synthetic Human Secretin in Children With Autism
NCT00065884	PHASE3	UNKNOWN	Valproate Response in Aggressive Autistic Adolescents
NCT00065962	PHASE3	COMPLETED	Secretin for the Treatment of Autism
NCT00252603	PHASE3	COMPLETED	Galantamine Versus Placebo in Childhood Autism
NCT00346736	PHASE3	COMPLETED	Use of Acupuncture In Children With Autistic Spectrum Disorder
NCT00352248	PHASE3	COMPLETED	Randomized Controlled Trial of Acupuncture Versus Sham Acupuncture in Autistic Spectrum Disorder
NCT00352352	PHASE3	COMPLETED	Use of Acupuncture In Children With Autistic Spectrum Disorder
NCT00355329	PHASE3	COMPLETED	Randomized Control Trial of Using Tongue Acupuncture in Autistic Spectrum Disorder Using PET Scan for Clinical Correlation
NCT00498173	PHASE3	COMPLETED	Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism
NCT00541346	PHASE3	COMPLETED	A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms